This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Favre, B.
Right arrow Articles by Ryder, N. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Favre, B.
Right arrow Articles by Ryder, N. S.

 Previous Article  |  Next Article 

Journal of Clinical Microbiology, October 2003, p. 4817-4819, Vol. 41, No. 10
0095-1137/03/$08.00+0     DOI: 10.1128/JCM.41.10.4817-4819.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.

Comparison of In Vitro Activities of 17 Antifungal Drugs against a Panel of 20 Dermatophytes by Using a Microdilution Assay

Bertrand Favre,{dagger} Bettina Hofbauer, Kwang-Soo Hildering,{ddagger} and Neil S. Ryder3*

Novartis Research Institute, Vienna, Austria

Received 11 February 2003/ Returned for modification 30 April 2003/ Accepted 29 July 2003


arrow
ABSTRACT
 
The in vitro activities of 17 antifungal drugs against a panel of 20 dermatophytes comprising 6 different species were determined using a microdilution assay according to the NCCLS M38-P method with some modifications. Terbinafine was the most potent systemic drug while tolnaftate and amorolfine were the most active topical agents.


arrow
TEXT
 
Most superficial infections caused by dermatophytes can be rapidly eradicated with topical antifungals. However, two common dermatophytoses, tinea capitis and tinea unguium, do not respond well to such treatment and require the use of systemic antimycotics to be cured (2, 8, 23). Numerous topical agents and several systemic ones are available, but comparison of their in vitro activity against dermatophytes has been hampered by the lack of a well accepted MIC assay for these fungi (1, 5, 9, 10, 13, 14, 18-20, 25). Recently, several groups have adapted the proposed reference method for broth dilution antifungal susceptibility testing of conidium-forming filamentous fungi (17) for developing a more specific assay for dermatophytes (6). Since the preparation of conidia inoculum is sometimes a challenge with dermatophytes, a microdilution assay appears to be the ideal format (5, 6, 13, 20). However, assay parameters, such as the temperature, duration, or growth inhibition endpoint, are still the subject of debate (11, 12, 21).

The NCCLS guidelines are primarily aimed toward susceptibility testing of clinical isolates. The aim of the present study was to establish an NCCLS-compatible assay, which was optimized for our primary purpose of evaluating investigative antifungal agents.

Twenty strains of dermatophytes, Trichophyton rubrum (n = 5), Trichophyton tonsurans (n = 5), Trichophyton mentagrophytes (n = 4), Microsporum canis (n = 4), Microsporum gypseum (n = 1), and Epidermophyton floccosum (n = 1), were employed. Five strains were obtained from either the fungal biodiversity center (Centralbureau voor Schimmelcultures, Utrecht, The Netherlands), T. mentagrophytes strain 560.66 (Novartis Fungal Index [NFI] 5606), T. tonsurans strains 171.65 (NFI 5177) and 729.88 (NFI 5178), or American Type Culture Collection (Manassas, Va.), T. rubrum strain 18759 (NFI 5182) and T. tonsurans strain 10217 (NFI 5176). The others were clinical isolates.

RPMI 1640 medium (Invitrogen) with L-glutamine and without bicarbonate was buffered at pH 7.0 with 0.165 M morpholinepropanesulfonic acid (Sigma). Terbinafine, naftifine, butenafine, voriconazole, and itraconazole were synthesized at Novartis. Fluconazole was extracted and purified from Diflucan tablets (Pfizer). Miconazole, amorolfine, and tolciclate were obtained from Janssen, Roche, and Montedison, respectively. Clotrimazole, econazole, ketoconazole, ciclopiroxolamine, tolnaftate, griseofulvine, and undecylenic acid were purchased from Sigma, while tioconazole was bought from U.S. Pharmacopeia. All drugs were dissolved and twofold serially diluted in dimethyl sulfoxide (DMSO).

All standard media were purchased from Merck. T. mentagrophytes, T. tonsurans, and E. floccosum were grown on Kimmig agar, T. rubrum was grown on potato dextrose agar, and M. canis and M. gypseum were grown on malt extract agar at 26°C for 2 to 3 weeks. Mycelium and spores were scraped from the plates and dispersed in a small volume of Sabouraud 2% dextrose broth (usually 20 ml for 25 plates) using a sterile glass homogenizer. After addition of 5% DMSO as a cryoprotectant, the fungal suspension was stored at -80°C (7). The viable count was determined by serially diluting the stock in 0.86% NaCl and spreading 50 µl/plate on the same agar medium as the one used for the inoculum preparation.

Microdilution plates with flat-bottom well (Greiner) were set up in accordance with the NCCLS M38-P reference method (17). The final concentration of DMSO was 1%, and the inoculum size was 5 x 103 CFU/ml. Plates were incubated for 4 to 5 days, depending on the growth in control wells without drug, at 30°C for E. floccosum and M. canis and 35°C for the other dermatophytes. Growth inhibition was scored visually with the aid of an inverted magnifying mirror from 4 to 0 according to the NCCLS M38-P reference method, and MIC of all tested drugs corresponded to the lowest concentration giving a score of 1 (equivalent to about 75% inhibition). After MIC determination, the total volume of each well, starting from the last well in which growth was observed up to the highest drug concentration tested, was transferred into glass tubes containing 5 ml of Sabouraud 2% dextrose broth (pH 6.5). Tubes were incubated for 1 week at 30°C, and growth was inspected visually after shaking. The minimal fungicidal concentration (MFC) corresponded to the lowest drug concentration (in the assay plate) at which no viable fungus remained. All experiments were repeated at least twice (topical agents) or more (systemic drugs). MICs usually did not differ by more than one dilution step.

For our purpose of evaluating drugs against a defined set of dermatophytes, large-scale preparation of inoculum with well-defined CFU is advantageous. Therefore, we initially compared MICs obtained with four drugs, terbinafine, itraconazole, fluconazole, and griseofulvine, against a few dermatophytes using either fresh inocula prepared according to the method of Jessup et al. (13) or frozen inocula. The results indicated that both freezing and the presence of mycelium in the inoculum did not significantly affect MICs of antifungals, in agreement with results obtained by Manavathu et al. (15).

The ideal incubation temperature, 28 to 35°C, and time for antifungal susceptibility testing of dermatophytes are still a matter of debate. In our hands, M. canis and E. floccosum grew very poorly at 35°C, so we decreased the temperature to 30°C for these two species. Concerning the incubation time, 4 to 5 days was found to be sufficient to observe prominent growth in control wells without drug with our restricted panel of dermatophytes, which were selected from a larger panel on the basis of their abundant conidium production and robust growth properties.

There is no consensus concerning the optimal growth inhibition endpoint for MICs (5, 6, 21). We uniformly adopted a score of 1 as the MIC for all the tested drugs, as recommended by Norris et al. (20). The obtained MIC results are presented in Table 1. Among the six systemic antifungals tested, fluconazole, griseofulvine, itraconazole, ketoconazole, terbinafine, and voriconazole, the allylamine terbinafine was the most potent agent. In our assay, voriconazole was significantly more active than itraconazole, in agreement with the findings of Fernandez-Torres et al. (6) but in contrast to the results of Perea et al. (21). The reason for these differences is unknown.


View this table:
[in this window]
[in a new window]
  		TABLE 1. MIC of 17 antifungals against a panel of 20 dermatophytesa

We also measured MFCs with a simple but rigorous method requiring complete elimination of viable particles in the culture well during the MIC incubation time, while MFC is often defined as a >=99% reduction of CFU (3, 4, 16, 22, 24). Amorolfine and the squalene epoxidase inhibitors, butenafine, naftifine, and terbinafine, were systematically fungicidal toward our panel of dermatophytes within the range of tested concentrations, >=32x the MIC at which 50% of the organisms were inhibited (Table 1).

In summary, the proposed microdilution assay for dermatophytes is convenient and reproducible. While parameters such as scoring range and MIC endpoint could be harmonized, it appears that the incubation temperature cannot be uniformly set at 35°C. The test strains were selected for adequate growth and normal susceptibility to standard drugs; we suggest that a comparable set of strains could be picked from any dermatophyte collection and used to obtain similar results. Among the systemic antifungals tested, terbinafine was the most potent, while tolnaftate and amorolfine were the most active topical agents.


arrow
ACKNOWLEDGMENTS
 
We thank Ingrid Leitner for the preparation of dermatophyte inocula.


arrow
FOOTNOTES
 
* Corresponding author. Mailing address: Infectious Diseases Biology, Room 4210, Novartis Institutes for Biomedical Research, Inc., 100 Technology Square, Cambridge, MA 02139. Phone: (617) 871-3143. Fax: (617) 871-7047. E-mail: neil.ryder{at}pharma.novartis.com. Back

{dagger} Present address: Department of Dermatology, University Hospital CHUV, Lausanne, Switzerland. Back

{ddagger} Present address: Igeneon, Vienna, Austria. Back

§ Present address: Novartis Institutes for Biomedical Research, Inc., Cambridge, MA 02139. Back


arrow
REFERENCES
 
    1
  1. Barchiesi, F., D. Arzeni, V. Camiletti, O. Simonetti, A. Cellini, A. M. Offidani, and G. Scalise. 2001. In vitro activity of posaconazole against clinical isolates of dermatophytes. J. Clin. Microbiol. 39:4208-4209.[Abstract/Free Full Text]
    2. 2
  2. Del Rosso, J. Q. 2000. Current management of onychomycosis and dermatomycoses. Curr. Infect. Dis. Rep. 2:438-445.[Medline]
    3. 3
  3. Espinel-Ingroff, A. 2001. In vitro fungicidal activities of voriconazole, itraconazole, and amphotericin B against opportunistic moniliaceous and dematiaceous fungi. J. Clin. Microbiol. 39:954-958.[Abstract/Free Full Text]
    4. 4
  4. Espinel-Ingroff, A., A. Fothergill, J. Peter, M. G. Rinaldi, and T. J. Walsh. 2002. Testing conditions for determination of minimum fungicidal concentrations of new and established antifungal agents for Aspergillus spp.: NCCLS collaborative study. J. Clin. Microbiol. 40:3204-3208.[Abstract/Free Full Text]
    5. 5
  5. Fernandez-Torres, B., A. J. Carrillo, E. Martin, A. Del Palacio, M. K. Moore, A. Valverde, M. Serrano, and J. Guarro. 2001. In vitro activities of 10 antifungal drugs against 508 dermatophyte strains. Antimicrob. Agents Chemother. 45:2524-2528.[Abstract/Free Full Text]
    6. 6
  6. Fernandez-Torres, B., H. Vazquez-Veiga, X. Llovo, M. Pereiro, Jr., and J. Guarro. 2000. In vitro susceptibility to itraconazole, clotrimazole, ketoconazole and terbinafine of 100 isolates of Trichophyton rubrum. Chemotherapy 46:390-394.[CrossRef][Medline]
    7. 7
  7. Georgopoulos, A. 1978. Deep-freeze preservation of fungi in liquid nitrogen as a basis for standardized inocula. Mykosen 21:19-23. (In German.)
    8. 8
  8. Gupta, A. K., P. Adam, N. Dlova, C. W. Lynde, S. Hofstader, N. Morar, J. Aboobaker, and R. C. Summerbell. 2001. Therapeutic options for the treatment of tinea capitis caused by Trichophyton species: griseofulvin versus the new oral antifungal agents, terbinafine, itraconazole, and fluconazole. Pediatr. Dermatol. 18:433-438.[CrossRef][Medline]
    9. 9
  9. Hazen, K. C. 1998. Fungicidal versus fungistatic activity of terbinafine and itraconazole: an in vitro comparison. J. Am. Acad. Dermatol. 38:S37-S41.[CrossRef][Medline]
    10. 10
  10. Hazen, K. C. 2000. Evaluation of in vitro susceptibility of dermatophytes to oral antifungal agents. J. Am. Acad. Dermatol. 43:125-129.
    11. 11
  11. Hofbauer, B., I. Leitner, and N. S. Ryder. 2002. In vitro susceptibility of Microsporum canis and other dermatophyte isolates from veterinary infections during therapy with terbinafine or griseofulvin. Med. Mycol. 40:1-5.[Medline]
    12. 12
  12. Jessup, C. J., N. S. Ryder, and M. A. Ghannoum. 2000. An evaluation of the in vitro activity of terbinafine. Med. Mycol. 38:155-159.[Medline]
    13. 13
  13. Jessup, C. J., J. Warner, N. Isham, I. Hasan, and M. A. Ghannoum. 2000. Antifungal susceptibility testing of dermatophytes: establishing a medium for inducing conidial growth and evaluation of susceptibility of clinical isolates. J. Clin. Microbiol. 38:341-344.[Abstract/Free Full Text]
    14. 14
  14. Korting, H. C., M. Ollert, and D. Abeck. 1995. Results of German multicenter study of antimicrobial susceptibilities of Trichophyton rubrum and Trichophyton mentagrophytes strains causing tinea unguium. Antimicrob. Agents Chemother. 39:1206-1208.[Abstract]
    15. 15
  15. Manavathu, E. K., J. Cutright, and P. H. Chandrasekar. 1999. Comparative study of susceptibilities of germinated and ungerminated conidia of Aspergillus fumigatus to various antifungal agents. J. Clin. Microbiol. 37:858-861.[Abstract/Free Full Text]
    16. 16
  16. Moore, C. B., D. Law, and D. W. Denning. 1993. In-vitro activity of the new triazole D0870 compared with amphotericin B and itraconazole against Aspergillus spp. J. Antimicrob. Chemother. 32:831-836.[Abstract/Free Full Text]
    17. 17
  17. National Committee for Clinical Laboratory Standards. 2000. Reference method for broth dilution antifungal susceptibility testing of conidium-forming filamentous fungi. Approved standard M38-A. National Committee for Clinical Laboratory Standards, Wayne, Pa.
    18. 18
  18. Niewerth, M., V. Splanemann, H. C. Korting, J. Ring, and D. Abeck. 1998. Antimicrobial susceptibility testing of dermatophytes—comparison of the agar macrodilution and broth microdilution tests. Chemotherapy 44:31-35.[Medline]
    19. 19
  19. Nimura, K., Y. Niwano, S. Ishiduka, and R. Fukumoto. 2001. Comparison of in vitro antifungal activities of topical antimycotics launched in 1990s in Japan. Int. J. Antimicrob. Agents 18:173-178.[CrossRef][Medline]
    20. 20
  20. Norris, H. A., B. E. Elewski, and M. A. Ghannoum. 1999. Optimal growth conditions for the determination of the antifungal susceptibility of three species of dermatophytes with the use of a microdilution method. J. Am. Acad. Dermatol. 40:S9-S13.[CrossRef][Medline]
    21. 21
  21. Perea, S., A. W. Fothergill, D. A. Sutton, and M. G. Rinaldi. 2001. Comparison of in vitro activities of voriconazole and five established antifungal agents against different species of dermatophytes using a broth macrodilution method. J. Clin. Microbiol. 39:385-388.[Abstract/Free Full Text]
    22. 22
  22. Pujol, I., C. Aguilar, J. Fernandez-Ballart, and J. Guarro. 2000. Comparison of the minimum fungicidal concentration of amphotericin B determined in filamentous fungi by macrodilution and microdilution methods. Med. Mycol. 38:23-26.
    23. 23
  23. Roberts, D. T. 1999. Onychomycosis: current treatment and future challenges. Br. J. Dermatol. 141(Suppl. 56):1-4.
    24. 24
  24. Tawara, S., F. Ikeda, K. Maki, Y. Morishita, K. Otomo, N. Teratani, T. Goto, M. Tomishima, H. Ohki, A. Yamada, K. Kawabata, H. Takasugi, K. Sakane, H. Tanaka, F. Matsumoto, and S. Kuwahara. 2000. In vitro activities of a new lipopeptide antifungal agent, FK463, against a variety of clinically important fungi. Antimicrob. Agents Chemother. 44:57-62.[Abstract/Free Full Text]
    25. 25
  25. Wildfeuer, A., H. P. Seidl, I. Paule, and A. Haberreiter. 1998. In vitro evaluation of voriconazole against clinical isolates of yeasts, moulds and dermatophytes in comparison with itraconazole, ketoconazole, amphotericin B and griseofulvin. Mycoses 41:309-319.[Medline]

Journal of Clinical Microbiology, October 2003, p. 4817-4819, Vol. 41, No. 10
0095-1137/03/$08.00+0     DOI: 10.1128/JCM.41.10.4817-4819.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Tong, Z., Widmer, F., Sorrell, T. C., Guse, Z., Jolliffe, K. A., Halliday, C., Lee, O. C., Kong, F., Wright, L. C., Chen, S. C. A. (2007). In Vitro Activities of Miltefosine and Two Novel Antifungal Biscationic Salts against a Panel of 77 Dermatophytes. Antimicrob. Agents Chemother. 51: 2219-2222 [Abstract] [Full Text]  
  • Barros, M. E. d. S., Santos, D. d. A., Hamdan, J. S. (2007). Evaluation of susceptibility of Trichophyton mentagrophytes and Trichophyton rubrum clinical isolates to antifungal drugs using a modified CLSI microdilution method (M38-A). J Med Microbiol 56: 514-518 [Abstract] [Full Text]  
  • Osborne, C. S., Leitner, I., Favre, B., Ryder, N. S. (2005). Amino Acid Substitution in Trichophyton rubrum Squalene Epoxidase Associated with Resistance to Terbinafine. Antimicrob. Agents Chemother. 49: 2840-2844 [Abstract] [Full Text]  
  • Santos, D. A., Hamdan, J. S. (2005). Evaluation of Broth Microdilution Antifungal Susceptibility Testing Conditions for Trichophyton rubrum. J. Clin. Microbiol. 43: 1917-1920 [Abstract] [Full Text]  

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Favre, B.
Right arrow Articles by Ryder, N. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Favre, B.
Right arrow Articles by Ryder, N. S.

Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»